Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $32.50.

A number of research analysts recently commented on BDSX shares. Canaccord Genuity Group set a $20.00 target price on shares of Biodesix and gave the company a “buy” rating in a research report on Friday, September 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Biodesix to a “sell” rating in a research report on Saturday, September 13th.

Insiders Place Their Bets

In other Biodesix news, Director Jack W. Schuler purchased 142,045 shares of the firm’s stock in a transaction that occurred on Friday, September 19th. The stock was purchased at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the purchase, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. This trade represents a 11.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have acquired 334,836 shares of company stock worth $2,611,362 and have sold 293 shares worth $2,461. 30.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Biodesix

Large investors have recently bought and sold shares of the business. Blair William & Co. IL boosted its stake in Biodesix by 33.3% during the 1st quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock worth $78,000 after purchasing an additional 31,000 shares during the period. XTX Topco Ltd acquired a new stake in Biodesix during the 1st quarter worth $64,000. Birchview Capital LP lifted its stake in shares of Biodesix by 2.8% in the 1st quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock worth $3,586,000 after acquiring an additional 154,937 shares during the period. Finally, Monashee Investment Management LLC lifted its stake in shares of Biodesix by 15.7% in the 1st quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock worth $2,532,000 after acquiring an additional 549,121 shares during the period. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Price Performance

Shares of BDSX opened at $6.83 on Friday. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $34.39. The firm’s 50 day moving average price is $7.70 and its 200 day moving average price is $7.45. The company has a market cap of $50.06 million, a P/E ratio of -1.18 and a beta of 0.98. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of 41.11.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Thursday, August 7th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by ($0.20). The company had revenue of $20.02 million during the quarter, compared to analyst estimates of $18.47 million. Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. Biodesix has set its FY 2025 guidance at EPS. On average, research analysts forecast that Biodesix will post -0.35 earnings per share for the current fiscal year.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.